Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma.
Mark GurnellAmr RadwanClaus BachertNjira LugogoSeong Ho ChoScott NashHaixin ZhangAsif Hameed KhanJuby Anne Jacob-NaraPaul J RoweYamo DenizPublished in: Journal of asthma and allergy (2024)
Dupilumab significantly reduced the requirement for SCS and improved asthma outcomes irrespective of history of asthma exacerbation or prior SCS use vs placebo in patients with CRSwNP and coexisting asthma, demonstrating concomitant reduction of SCS use and asthma disease burden in these patients.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- allergic rhinitis
- end stage renal disease
- chronic kidney disease
- type diabetes
- atopic dermatitis
- ejection fraction
- newly diagnosed
- randomized controlled trial
- air pollution
- metabolic syndrome
- peritoneal dialysis
- adipose tissue
- prognostic factors
- patient reported outcomes
- study protocol